SeaStar Medical Holding Corporation ICU
1.88 USD -0.04 (-2.08%)
At closeNov 6, 2026, 7:46 PM EST
1.88 0.00 0.00%
After hours · Nov 6, 7:46 PM ET
1.88 Day range 1.99
1.88 52-week range 5.38
- YTD
- -21.67%
- 1 year
- -59.22%
- Market cap
- 9.99M
- EPS (ttm)
- -2.97
- Shares out
- 4.46M
- Forward P/E
- -0.77
- YTD return
- -21.67%
- 1-year return
- -59.22%
- Volume
- 58.73K
- Avg volume
- 159.86K
- Open
- 1.93
- Previous close
- 1.92
- Day's range
- 1.88 – 1.99
- 52-week range
- 1.88 – 5.38
- Beta
- -1.06
- Price target
- 7.00 (+272.3%)
1Y -3.02 (-61.63%)
Key statistics
- Enterprise value
- 10.13M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.69M
- Total cash
- 1.18M
- Total debt
- 3.14M
- Return on equity
- 0.00%
- Short % of float
- 8.59%
- 50-day average
- 2.76
- 200-day average
- 7.91
Analyst view
Price target (mean) 7.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ICU Revenue — quarterly 615.00K
ICU Net income — quarterly -3.73M
ICU EPS — quarterly -0.91
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -1.10 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -1.03 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -4.75 | — | — |
| Apr 16, 2024 | Dec 1, 2023 | 0.00 | -4.75 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -3.00 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -6.25 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 20, 2023 | Maxim Group | init | — | Buy |
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- seastarmedical.com
News
ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London 
ICU Medical Q3 Earnings Call Highlights 
SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026 
Stellantis In The ICU, Struggling To Bounce Back From Financial Collapse 
SeaStar Medical Announces FDA Determines QUELIMMUNE Pediatric SAVE Registry Has Fulfilled Post-Approval Study Requirements 
FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients - SeaStar Medical Reports 65.1% Survival Rate At Day 90 In Its QUELIMMUNE SAVE Registry Analysis Presented At ASN Kidney Week 2026
- SeaStar Medical Receives FDA's Medical Breakthrough Device Designation For Its Selective Cytopheretic Device Therapy To Treat Hyperinflammation
12 Health Care Stocks Moving In Monday's Intraday Session 
12 Health Care Stocks Moving In Friday's Intraday Session
Your note
Sign in to keep a note on ICU — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNETT RICK | Director | Stock Award(Grant) | Apr 11, 2024 | 86,664 |
| BARON CARYL | Chief Financial Officer | Stock Award(Grant) | Nov 28, 2023 | 139,872 |
| CHUNG KEVIN | Officer | Purchase | Nov 17, 2024 | 13,685 |
| COLLINS ALLAN | Director | Stock Award(Grant) | Apr 11, 2024 | 54,343 |
| GREEN DAVID A | Chief Financial Officer | Stock Award(Grant) | Aug 29, 2024 | 10,323 |
| LOBO ANDRES | Director | Stock Award(Grant) | Apr 11, 2024 | 40,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.58% | 70,317 | 139.93K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.89% | 39,812 | 79.22K | Sep 29, 2024 |
| Thoroughbred Financial Services LLC | 0.25% | 11,225 | 22.34K | Sep 29, 2024 |
| Blackrock Inc. | 0.20% | 9,126 | 18.16K | Sep 29, 2024 |
| PNC Financial Services Group, Inc. | 0.03% | 1,500 | 2.98K | Sep 29, 2024 |
| Blue Trust, Inc. | 0.02% | 888 | 1.77K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.92% | 41,263 | 82.11K | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.61% | 27,412 | 54.55K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.52% | 23,088 | 45.95K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 7,505 | 14.93K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 5,719 | 11.38K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 1,423 | 2.83K | Oct 30, 2024 |